Skip Nav Destination
Issues
1 March 2008
-
Cover Image
Cover Image
Due to genetic instability, cancer cells readily develop heritable variants that escape destruction or growth arrest. For example, solid tumors 1cm in diameter (~109 cancer cells) commonly contain variant cancer cells that can no longer be killed by T cells directly because of loss of antigen, MHC class I down-regulation, or antigen mutation. Stromal cells within tumors are genetically much more stable and can cross-present tumor-specific antigens released from cancer cells as targets for T cells. Zhang and colleagues demonstrate that a single transfer of T cells targeting only antigen-loaded stromal cells (cancer cells lacked the presenting MHC molecule) caused long-term equilibrium between host and cancer. Untreated tumors (a), shown here on day 20, killed mice within a month and consisted of a homogenous, well-vascularized mass of rapidly proliferating cancer cells with little evidence of apoptosis or necrosis. In contrast, T-cell–treated tumors (b) became necrotic with only a rim of viable, mitotic cancer cells adjacent to lymphocytes and pre-existing vasculature. These tumors persisted for months, shown here at day 70. Tumor eradication is obviously preferable to tumor arrest; however, for many aggressively growing, rapidly lethal cancers, long-term arrest of growth with equilibrium between the host and cancer would be an acceptable goal. Therefore, targeting stromal cells that cross-present antigens released from cancer cells may prove to become an important new approach to cancer therapy. For details, see the article by Zhang and colleagues on page 1563 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 0008-5472
EISSN 1538-7445
Journal Archive
Cancer Research (1941-Present; volumes 1-current)
(ISSN 0008-5472) Published twice monthly since 1987. From 1941-1986, published monthly.The American Journal of Cancer (1931-1940; volumes 15-40)
(ISSN 0099-7374) Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.The Journal of Cancer Research (1916-1930); volumes 1-14)
(ISSN 0099-7013) Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.Table of Contents
Reviews
Priority Reports
Molecular Biology, Pathobiology, and Genetics
Chromosomal Breakpoints in Primary Colon Cancer Cluster at Sites of Structural Variants in the Genome
Jordi Camps; Marian Grade; Quang Tri Nguyen; Patrick Hörmann; Sandra Becker; Amanda B. Hummon; Virginia Rodriguez; Settara Chandrasekharappa; Yidong Chen; Michael J. Difilippantonio; Heinz Becker; B. Michael Ghadimi; Thomas Ried
A Novel Recurrent Chromosomal Inversion Implicates the Homeobox Gene Dlx5 in T-Cell Lymphomas from Lck-Akt2 Transgenic Mice
Yinfei Tan; Roman A. Timakhov; Mamta Rao; Deborah A. Altomare; Jinfei Xu; Zemin Liu; Qingshen Gao; Suresh C. Jhanwar; Antonio Di Cristofano; David L. Wiest; Janice E. Knepper; Joseph R. Testa
Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth
Tsutomu Ohta; Kumiko Iijima; Mamiko Miyamoto; Izumi Nakahara; Hiroshi Tanaka; Makiko Ohtsuji; Takafumi Suzuki; Akira Kobayashi; Jun Yokota; Tokuki Sakiyama; Tatsuhiro Shibata; Masayuki Yamamoto; Setsuo Hirohashi
Cell, Tumor, and Stem Cell Biology
A Human Breast Cell Model of Preinvasive to Invasive Transition
Aylin Rizki; Valerie M. Weaver; Sun-Young Lee; Gabriela I. Rozenberg; Koei Chin; Connie A. Myers; Jamie L. Bascom; Joni D. Mott; Jeremy R. Semeiks; Leslie R. Grate; I. Saira Mian; Alexander D. Borowsky; Roy A. Jensen; Michael O. Idowu; Fanqing Chen; David J. Chen; Ole W. Petersen; Joe W. Gray; Mina J. Bissell
EBV MicroRNAs in Primary Lymphomas and Targeting of CXCL-11 by ebv-mir-BHRF1-3
Tianli Xia; Andrea O'Hara; Iguaracyra Araujo; Jose Barreto; Eny Carvalho; Jose Bahia Sapucaia; Juan Carlos Ramos; Estela Luz; Celia Pedroso; Michele Manrique; Ngoc L. Toomey; Carlos Brites; Dirk P. Dittmer; William J. Harrington, Jr.
Anti–Tumor Necrosis Factor Therapy Inhibits Pancreatic Tumor Growth and Metastasis
Jan-Hendrik Egberts; Vera Cloosters; Andreas Noack; Bodo Schniewind; Lutz Thon; Stefanie Klose; Bastian Kettler; Corinna von Forstner; Christian Kneitz; Jürgen Tepel; Dieter Adam; Harald Wajant; Holger Kalthoff; Anna Trauzold
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Expression of HER2 and Estrogen Receptor α Depends upon Nuclear Localization of Y-Box Binding Protein-1 in Human Breast Cancers
Teruhiko Fujii; Akihiko Kawahara; Yuji Basaki; Satoshi Hattori; Kazutaka Nakashima; Kenji Nakano; Kazuo Shirouzu; Kimitoshi Kohno; Takashi Yanagawa; Hideaki Yamana; Kazuto Nishio; Mayumi Ono; Michihiko Kuwano; Masayoshi Kage
Immunology
Endocrinology
Clinical Research
Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics
Patrizia Sini; Ivana Samarzija; Fabienne Baffert; Amanda Littlewood-Evans; Christian Schnell; Andreas Theuer; Sven Christian; Anja Boos; Holger Hess-Stumpp; John A. Foekens; Buddy Setyono-Han; Jeanette Wood; Nancy E. Hynes
Prevention
Corrections
Advertisement